Skip to content

    Parkinson's Disease Health Center

    Font Size
    A
    A
    A

    Therapy for Parkinson's Disease Moving in the Right Direction

    By
    WebMD Health News

    Oct. 17, 2000 -- How far have we come in finding the best treatment for Parkinson's disease? Recent research indicates that we're not quite there yet, but we are getting closer. Scientists are currently trying to determine whether a new class of drugs, developed in the last few years, can improve quality of life in these patients, and a recent study suggests they might.

    More than 1 million Americans have been diagnosed with Parkinson's disease, which causes symptoms such as trembling even when the body is at rest, muscle rigidity, and loss of the ability to control voluntary movements. The disease is caused by the progressive death of nerve cells in the brain that produce a chemical called dopamine, which helps the central nervous system control normal movements.

    Since the 1960s, standard therapy for Parkinson's disease has been the drug levodopa, which is marketed as Sinemet or Atamet. In the brain, levodopa is converted into dopamine to replace stores of the naturally occurring chemical.

    But levodopa can be both a blessing and a curse. While the drug is effective at reversing motion problems, it also causes severe side effects in about 90% of all patients who use it long term. Side effects can include nausea, dizziness, hallucinations, and other abnormal, involuntary movements that often interfere with the patients' intended normal movements.

    In addition, more and more of the drug is needed as the disease progresses, often making symptoms even worse. The symptoms can return suddenly and without warning, or they can wax and wane. It is a cruel irony, then, that the therapy itself often contributes to the ultimate disability associated with Parkinson's disease.

    Mirapex (pramipexole) is one of a new category of drugs called dopamine agonists. Instead of being converted into dopamine in the brain, dopamine agonists boost the brain's ability to produce and process the chemical.

    In a study published in the Oct. 18 issue of TheJournal of the American Medical Association, Mirapex reduced the risk of developing movement problems by as much as 55% in people who took it compared to patients who took levodopa. The research was conducted by investigators from the Parkinson Study Group.

    1 | 2 | 3

    Today on WebMD

    Parkinsons disease illustration
    Causes, symptoms, and treatments.
    hands on walker
    How does the disease progress?
     
    man with serious expression
    8 common questions and answers.
    intelligence quotient illustration
    What are the advantages of DBS?
     
    Parkinsons Disease Medications
    Article
    Questions Doctor Parkinsons
    Article
     
    Eating Right
    Article
    Parkinsons Exercise
    Article
     
    daughter consoling depressed mother
    Article
    senior man's hands
    Article
     
    Parkinsons Daily
    Article
    Acupunture
    Article